6-amino-1-hydroxyhexane-1,1-diphosphonate and cholecalciferol

6-amino-1-hydroxyhexane-1,1-diphosphonate has been researched along with cholecalciferol in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anastasi, G; Atteritano, M; Catalano, A; Frisina, N; Gaudio, A; Lasco, A; Melloni, D; Morabito, N; Trifiletti, A	1
Cantatore, FP; Colucci, S; Corrado, A; Grano, M	1
Adami, S; Braga, V; Dhangana, R; Fracassi, E; Gatti, D; Kalpakcioglu, B; Rossini, M; Viapiana, O	1

Trials

1 trial(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and cholecalciferol

Article	Year
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:11 Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Density; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate	2004

Article

Year

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:11

Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Density; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate

2004

Other Studies

2 other study(ies) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and cholecalciferol

Article	Year
Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clinical rheumatology, 2005, Volume: 24, Issue:5 Topics: Adult; Aged; Cells, Cultured; Cholecalciferol; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Osteoarthritis; Osteoblasts; Osteocalcin; Osteoporosis	2005
Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism. Calcified tissue international, 2011, Volume: 89, Issue:1 Topics: Aged; Alkaline Phosphatase; Bone Density Conservation Agents; Cholecalciferol; Collagen Type I; Diphosphonates; Female; Femur Neck; Humans; Hyperparathyroidism, Primary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Time	2011

Article

Year

Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects.

Clinical rheumatology, 2005, Volume: 24, Issue:5

Topics: Adult; Aged; Cells, Cultured; Cholecalciferol; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Osteoarthritis; Osteoblasts; Osteocalcin; Osteoporosis

2005

Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism.

Calcified tissue international, 2011, Volume: 89, Issue:1

Topics: Aged; Alkaline Phosphatase; Bone Density Conservation Agents; Cholecalciferol; Collagen Type I; Diphosphonates; Female; Femur Neck; Humans; Hyperparathyroidism, Primary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Time

2011